ARV-393 demonstrated significant single-agent activity in models of nodal T-follicular helper cell lymphoma, ...

Congress, held from June 12 to June 15 in Milan, Italy, updated results from the Phase II registrational iMMagine-1 study ...

Congress, hematology experts highlight breakthroughs in treatment, the importance of patient voices, and challenges in making innovations accessible worldwide.

A compelling session at the EHA Congress explored how space research is reshaping our understanding of hematologic processes.

Sessions and posters at the 2025 European Hematology Association Congress evaluated the potential and real-world practices of using artificial intelligence (AI) to predict and improve outcomes for ...

Bristol-Myers Squibb Company (NYSE: BMY) is one of the best stocks to buy for beginners now. On June 12, Bristol Myers Squibb ...

Novartis has shared positive results from a phase 3b study of Fabhalta (iptacopan) in a new population of patients with the ...

The lack of therapeutic precision in treatment of myeloid malignancies is in sharp contrast with the fact that myeloid cancers represent the perhaps best characterized cancers of all at the cellular, ...

Experts reassess endpoints, patient selection, targets, and timing for the development of successful immune-based treatments ...

Analysts at Truist Securities called J&J’s CAR-T readout “compelling,” noting that the efficacy figures could position the ...

to be presented at the European Hematology Association 2025 Congress (EHA2025) in Milan, Italy. The Company will host a conference call and webcast featuring LOTIS-7 trial principal investigator ...